ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 July 10, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 6, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 13, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society June 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections May 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 2, 2023 Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 April 20, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology April 12, 2023 Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last » Displaying 11 - 20 of 32
Year None20232022202120202019201820172016 July 10, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 6, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 13, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society June 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections May 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 2, 2023 Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 April 20, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology April 12, 2023 Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last » Displaying 11 - 20 of 32
July 10, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
June 13, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
May 2, 2023 Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
April 20, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology